Backed by Capital Croissance and Turenne Capital since 2014, who remain minority reinvestors in the new transaction, BIOBank, led by Patrick Joucla, now pursues its expansion alongside New Alpha Verto.
BIOBank is a top French human origin bone bank who provide services from bone collection (femoral heads) to transformation, and then the distribution of virally inactivated and sterile bone grafts used in orthopaedic and dental surgery.
Founded in 1999, the company generates a turnover of c. €12m.
With almost 130 partnerships with healthcare institutions and the collection of c. 9,000 femur-heads in 2017, BIOBank has strengthened its position as the leader of the French allograft market.
With New Alpha Verto, the company intends to develop further R&D projects and to accelerate its international expansion. BIOBank also wishes to expand through external growth, and is already exploring two projects with high value creation.
